Literature DB >> 16871466

Drug evaluation: Degarelix--a potential new therapy for prostate cancer.

Christian Doehn1, Martin Sommerauer, Dieter Jocham.   

Abstract

Ferring Research Ltd and licensee Astellas Pharma Inc are developing the gonadotropin-releasing hormone antagonist degarelix as a potential subcutaneous treatment for prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16871466

Source DB:  PubMed          Journal:  IDrugs        ISSN： 1369-7056


  5 in total

1.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02

2.  Degarelix.

Authors:  James E Frampton; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

3.  Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Authors:  Charlotte Guyader; Jocelyn Céraline; Eléonore Gravier; Aurélie Morin; Sandrine Michel; Eva Erdmann; Gonzague de Pinieux; Florence Cabon; Jean-Pierre Bergerat; Marie-France Poupon; Stéphane Oudard
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

4.  Evaluation of degarelix in the management of prostate cancer.

Authors:  Hendrik Van Poppel
Journal:  Cancer Manag Res       Date:  2010-01-25       Impact factor: 3.989

Review 5.  Degarelix and its therapeutic potential in the treatment of prostate cancer.

Authors:  Christian Doehn; Martin Sommerauer; Dieter Jocham
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.